AMPHOTERICIN B
Total Payments
$33,675
Transactions
1
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $33,675 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $33,675 | 1 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Fungal Infections Post-Influenza among Lung Transplant Recipients | Astellas Pharma Global Development | $33,675 | 0 |
Top Doctors Receiving Payments for AMPHOTERICIN B
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Pittsburgh, PA | $33,675 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $33,675
- Total Doctors 0
- Transactions 1
About AMPHOTERICIN B
AMPHOTERICIN B is a drug associated with $33,675 in payments to 0 healthcare providers, recorded across 1 transactions in the CMS Open Payments database. The primary manufacturer is Astellas Pharma Global Development.
Payment data is available from 2018 to 2018. In 2018, $33,675 was paid across 1 transactions to 0 doctors.
The most common payment nature for AMPHOTERICIN B is "Unspecified" ($33,675, 100.0% of total).
AMPHOTERICIN B is associated with 1 research study, including "Fungal Infections Post-Influenza among Lung Transplant Recipients" ($33,675).